Valeritas (NASDAQ:VLRX) issued its quarterly earnings data on Friday. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07, MarketWatch Earnings reports. The firm had revenue of $6.93 million during the quarter. Valeritas had a negative net margin of 205.12% and a negative return on equity of 1,768.69%. Valeritas updated its FY 2018 guidance to EPS.
NASDAQ VLRX traded down $0.12 during trading on Friday, reaching $1.08. 684,617 shares of the stock traded hands, compared to its average volume of 355,958. The stock has a market cap of $28.59 million, a P/E ratio of -0.13 and a beta of 2.58. The company has a debt-to-equity ratio of 13.66, a quick ratio of 3.42 and a current ratio of 4.03. Valeritas has a fifty-two week low of $0.78 and a fifty-two week high of $6.79.
A number of hedge funds and other institutional investors have recently modified their holdings of VLRX. Essex Investment Management Co. LLC acquired a new position in Valeritas during the second quarter valued at approximately $448,000. Bainco International Investors acquired a new position in Valeritas during the second quarter valued at approximately $228,000. Finally, C WorldWide Group Holding A S grew its holdings in Valeritas by 28.0% during the second quarter. C WorldWide Group Holding A S now owns 316,194 shares of the company’s stock valued at $424,000 after purchasing an additional 69,216 shares during the period. Hedge funds and other institutional investors own 7.38% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Valeritas (VLRX) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS” was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.wkrb13.com/2018/11/10/valeritas-vlrx-releases-quarterly-earnings-results-beats-expectations-by-0-07-eps.html.
Valeritas Company Profile
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.